#1 Clinical Trials Search in Europe

Taletrectinib

Taletrectinib is an innovative drug currently being studied in clinical trials for the treatment of various advanced cancers, including metastatic breast cancer and non-small cell lung cancer (NSCLC). This article explores the ongoing research on Taletrectinib, its potential benefits, and its role in targeting specific genetic mutations in cancer cells.

Table of Contents

What is Taletrectinib?

Taletrectinib, also known as AB-106 or DS-6051b, is a new drug being studied for its potential to treat certain types of cancer[2]. It is classified as a tyrosine kinase inhibitor (TKI), which is a type of targeted therapy that works by blocking specific proteins involved in cancer growth[1].

How Does Taletrectinib Work?

Taletrectinib is designed to target and inhibit specific proteins called ROS1 and TRK. These proteins can become overactive in certain cancers, leading to uncontrolled cell growth. By blocking these proteins, taletrectinib aims to slow down or stop cancer progression[1].

Specifically, taletrectinib has shown activity against:

  • ROS1: A protein that, when altered, can drive cancer growth in some lung cancers
  • NTRK1 and NTRK3: Proteins that, when altered, can contribute to various types of cancers
  • Other proteins: ACK, ALK, DDR1, and LTK, which may also play roles in cancer development

Importantly, taletrectinib has demonstrated effectiveness against certain mutations that make cancers resistant to other treatments, potentially offering hope for patients whose cancers have stopped responding to other therapies[1].

What Conditions Does Taletrectinib Treat?

Taletrectinib is being studied for several types of cancer, including:

  1. Non-Small Cell Lung Cancer (NSCLC): Specifically, NSCLC that is positive for ROS1 gene alterations. This is a type of lung cancer where the ROS1 protein is abnormally active[2][3].
  2. Metastatic Breast Cancer: Particularly a type called Invasive Lobular Cancer (ILC) with mutations in a gene called CDH1[1].
  3. Other Solid Tumors: The drug is also being investigated for its potential in treating other types of solid tumors that have specific genetic alterations[2].

Ongoing Clinical Trials

Several clinical trials are currently underway to evaluate the effectiveness and safety of taletrectinib:

  1. Trial for Metastatic Breast Cancer: This study is looking at taletrectinib in patients with advanced breast cancer that has a specific genetic mutation (CDH1)[1].
  2. Trial for ROS1-Positive NSCLC: This global study is testing taletrectinib in patients with advanced lung cancer that has a ROS1 gene alteration[2].
  3. Comparative Trial for NSCLC: This large study is comparing taletrectinib to a standard treatment (crizotinib) in patients with ROS1-positive lung cancer who haven’t been treated with this type of drug before[3].

How is Taletrectinib Administered?

Taletrectinib is an oral medication, which means it’s taken by mouth. The dosage can vary depending on the specific trial and condition being treated:

  • In some trials, it’s given as 600mg once daily[1][3].
  • Other trials are testing doses of 400mg or 600mg once daily[2].
  • The medication is typically taken in cycles, with each cycle lasting 21 or 28 days[1][3].

Patients usually continue taking taletrectinib until their disease progresses, they experience unacceptable side effects, or they meet other criteria for stopping treatment[3].

Potential Side Effects

As with all medications, taletrectinib may cause side effects. The full range of potential side effects is still being studied in clinical trials. Researchers are closely monitoring patients for:

  • Adverse events (unexpected medical problems that occur during treatment)
  • Changes in laboratory test results
  • Changes in vital signs
  • Abnormal heart rhythms (detected by ECG)
  • Changes in eye health

It’s important to note that not all patients will experience side effects, and the severity can vary from person to person. If you’re participating in a clinical trial or receiving this medication, your healthcare team will closely monitor you for any side effects[2].

Future Prospects

Taletrectinib shows promise in treating certain types of cancer, particularly those with specific genetic alterations. The ongoing clinical trials will help determine:

  • How effective taletrectinib is compared to existing treatments
  • Its safety profile and potential side effects
  • Which patients are most likely to benefit from this treatment
  • Its effectiveness in treating cancer that has spread to the brain

Researchers are also studying how taletrectinib affects patients’ quality of life, which is an important consideration in cancer treatment[3].

As research continues, taletrectinib may become an important new option for patients with certain types of cancer, particularly those who have not responded well to other treatments.

Aspect Details
Drug Name Taletrectinib (also known as AB-106 or DS-6051b)
Target Cancers Metastatic breast cancer (ILC with CDH1 mutations), Non-small cell lung cancer (ROS1 positive)
Mechanism of Action ROS1 and TRK family inhibitor
Administration Oral, 400-600mg once daily
Trial Phases Phase II and Phase III
Primary Outcomes Objective Response Rate (ORR), Progression-Free Survival (PFS)
Secondary Outcomes Safety and tolerability, Duration of Response, Quality of Life assessments
Unique Features Activity against mutations conferring resistance to other drugs, potential for treating brain metastases

FAQ

  • What is Taletrectinib? Taletrectinib is a potent, highly selective, orally bioavailable drug that inhibits ROS1 and TRK family proteins. It is being studied for its potential to treat various advanced cancers, particularly those with specific genetic mutations.
  • What types of cancer is Taletrectinib being tested for? Taletrectinib is currently being tested in clinical trials for metastatic breast cancer, specifically invasive lobular cancer (ILC) with CDH1 mutations, and non-small cell lung cancer (NSCLC) with ROS1 gene fusions.
  • How is Taletrectinib administered? Taletrectinib is typically administered orally, with dosages ranging from 400mg to 600mg once daily, depending on the specific trial and patient group.
  • What are the main goals of the Taletrectinib clinical trials? The main goals of these trials are to evaluate the safety, tolerability, and efficacy of Taletrectinib in treating advanced cancers. Researchers are measuring outcomes such as objective response rate, progression-free survival, and overall survival.
  • Are there any side effects associated with Taletrectinib? As with any medication, Taletrectinib may have side effects. The clinical trials are closely monitoring patients for adverse events, including laboratory abnormalities, changes in vital signs, and any other health issues that may arise during treatment.

Ongoing Clinical Trials on Taletrectinib

  • Study of Taletrectinib for Patients with Advanced or Metastatic ROS1 Positive Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain

Glossary

  • Taletrectinib: A potent, highly selective, orally bioavailable drug that inhibits ROS1 and TRK family proteins, being studied for the treatment of various advanced cancers.
  • ROS1: A gene that, when altered, can contribute to the development of certain cancers, particularly non-small cell lung cancer.
  • TRK family: A group of proteins involved in cell signaling that, when altered, can lead to cancer growth.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Invasive Lobular Cancer (ILC): A type of breast cancer that begins in the milk-producing glands (lobules) of the breast.
  • CDH1 mutation: A genetic alteration in the CDH1 gene, which is associated with certain types of cancer, including some breast cancers.
  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form of the disease, accounting for about 80-85% of all cases.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Tyrosine Kinase Inhibitor (TKI): A type of drug that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.
  • Intracranial metastases: Cancer that has spread to the brain from its original site in another part of the body.
  • Pharmacokinetic (PK) profile: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References